The Cancer Center Protocol Review and Monitoring System oversees and ensures the scientific merit, priorities, and progress of all cancer clinical studies conducted at the University of Virginia (UVA). A Protocol Review Committee (PRC), appointed by the UVA Cancer Center Director and administratively-supported by the Office for Clinical Research, has been given the authority and charge to carry out this mandate. The PRC is chaired by James Larner, MD. Its primary goal is to ensure that investigator- and industryinitiated cancer research studies involving human subjects conducted at the UVA Cancer Center are: (1) scientifically and statistically sound;(2) appropriately designed;(3) feasible for completion;and (4) in compliance with NIH guidelines for human studies. The PRC also plays an important role in mediating competing studies by requiring an agreed upon institutional prioritization plan, and closely monitors the accrual progress of studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-22
Application #
8566500
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
22
Fiscal Year
2013
Total Cost
$69,122
Indirect Cost
$28,210
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Heuslein, Joshua L; Murrell, Kelsey P; Leiphart, Ryan J et al. (2016) Vascular growth responses to chronic arterial occlusion are unaffected by myeloid specific focal adhesion kinase (FAK) deletion. Sci Rep 6:27029
Ma, Zhenjun; Kim, Youngchul; Hu, Feifang et al. (2016) Point success rate for patient therapeutic response prediction by continuous biomarker scores. Stat Methods Med Res 25:1638-47
Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother 65:1201-12
Pelkofski, Elizabeth; Stine, Jessica; Wages, Nolan A et al. (2016) Cervical Cancer in Women Aged 35 Years and Younger. Clin Ther 38:459-66
Showalter, Timothy N; Camacho, Fabian; Cantrell, Leigh A et al. (2016) Determinants of Quality Care and Mortality for Patients With Locally Advanced Cervical Cancer in Virginia. Medicine (Baltimore) 95:e2913
Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunol Immunother 65:1189-99
Cross, A M; Wilson, A L; Guerrero, M S et al. (2016) Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells. Oncogene 35:5850-5859
Kolpaczynska, Milena; DeRosa, Christopher A; Morris, William A et al. (2016) Thienyl Difluoroboron β-Diketonates in Solution and Polylactide Media. Aust J Chem 69:537-545
Sloane, Hillary S; Landers, James P; Kelly, Kimberly A (2016) Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors. J Mol Diagn 18:546-53
Cheng, Bei; He, Huacheng; Huang, Tao et al. (2016) Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy. J Biomed Nanotechnol 12:435-49

Showing the most recent 10 out of 413 publications